Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Income from Continuing Operations (2022 - 2025)

Taysha Gene Therapies' Income from Continuing Operations history spans 4 years, with the latest figure at 30870000.0 for Q3 2025.

  • For Q3 2025, Income from Continuing Operations fell 29.62% year-over-year to 30870000.0; the TTM value through Sep 2025 reached 94149000.0, down 15.66%, while the annual FY2024 figure was 84621000.0, 14.56% down from the prior year.
  • Income from Continuing Operations for Q3 2025 was 30870000.0 at Taysha Gene Therapies, down from 24911000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 15038000.0 in Q4 2023 and bottomed at 55072000.0 in Q4 2022.
  • The 4-year median for Income from Continuing Operations is 23815000.0 (2024), against an average of 26734000.0.
  • The largest annual shift saw Income from Continuing Operations skyrocketed 72.69% in 2023 before it tumbled 43.36% in 2024.
  • A 4-year view of Income from Continuing Operations shows it stood at 55072000.0 in 2022, then skyrocketed by 72.69% to 15038000.0 in 2023, then decreased by 21.39% to 18254000.0 in 2024, then plummeted by 69.11% to 30870000.0 in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Income from Continuing Operations are 30870000.0 (Q3 2025), 24911000.0 (Q2 2025), and 20114000.0 (Q1 2025).